Evidence map›Paper›PMID 32159140›Full record

ReviewMaterials today. Bio2019

Bioinks and bioprinting technologies to make heterogeneous and biomimetic tissue constructs.

N Ashammakhi, S Ahadian, C Xu, H Montazerian, H Ko, R Nasiri, N Barros, A Khademhosseini

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Bioprinted skin: from lab bench to clinic, what matters now and what's next.Frontiers in bioengineering and biotechnology · 2026
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

N AshammakhiCenter for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, CA, 90095, USA.
S AhadianCenter for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, CA, 90095, USA.
C XuCenter for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, CA, 90095, USA.
H MontazerianCenter for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, CA, 90095, USA.
H KoCenter for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, CA, 90095, USA.
R NasiriCenter for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, CA, 90095, USA.
N BarrosCenter for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, CA, 90095, USA.
A KhademhosseiniCenter for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, CA, 90095, USA.

Funding

Microengineered Osteons for Bone Tissue EngineeringR01AR057837 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2010 to 2018
$5.1M
3D printed muscle-bone organ implant for treating large injuriesR01AR073135 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, JANG, HAE LIN · 2018 to 2022
$2.2M
Rapid 3D bioprinting of biomimetic vascularized tissue constructsR01EB021857 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, DOKMECI, MEHMET REMZI · 2016 to 2019
$2.1M
NIAMS NIH HHS R01 AR057837NIAMS NIH HHS R01 AR073135NIBIB NIH HHS R01 EB021857
6 · The paper itself

Abstract

The native tissues are complex structures consisting of different cell types, extracellular matrix materials, and biomolecules. Traditional tissue engineering strategies have not been able to fully reproduce biomimetic and heterogeneous tissue constructs because of the lack of appropriate biomaterials and technologies. However, recently developed three-dimensional bioprinting techniques can be leveraged to produce biomimetic and complex tissue structures. To achieve this, multicomponent bioinks composed of multiple biomaterials (natural, synthetic, or hybrid natural-synthetic biomaterials), different types of cells, and soluble factors have been developed. In addition, advanced bioprinting technologies have enabled us to print multimaterial bioinks with spatial and microscale resolution in a rapid and continuous manner, aiming to reproduce the complex architecture of the native tissues. This review highlights important advances in heterogeneous bioinks and bioprinting technologies to fabricate biomimetic tissue constructs. Opportunities and challenges to further accelerate this research area are also described.

Indexed as

BiofabricationRegenerative medicineThree-dimensional bioprintingTissue engineering

Identifiers

PMID32159140
PMCPMC7061634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.